Race Oncology Ltd has released a press release.
MD Anderson Preclinical AML Study on Zantrene Published
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race raises $29.7 million in oversubscribed SPP
- Expanded Heart Protection Discovery for Zantrene
- Race Oncology: Notification regarding unquoted securities - RAC
- Race Oncology Investor Presentation - November 2021
- Race Oncology Share Purchase Plan
Later from Racura Oncology
- Race Oncology: Application for quotation of securities - RAC
- Compelling Zantrene Preclinical Kidney Cancer Data
- Race Oncology: ASX Small and Mid-Cap Conference Presentation
- Zantrene highly effective in EMD AML Mouse Model
- Supply Agreement for EMD AML Trial
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology